Amgen Financial Ratios

Amgen Inc -- USA Stock  

USD 186.11  0.18  0.10%

We suggest you to use Amgen Inc fundamental analysis to see if markets are presently mispricing the company. In plain English you can use it to find out if Amgen Inc is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found thirty-eight available fundamental indicators for Amgen Inc which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Amgen Inc fundamentals including its EBITDA, Cash Flow from Operations and the relationship between Price to Book and Total Debt . Given that Amgen Inc has Price to Earning of 16.97 times, we suggest you validate Amgen Inc prevailing market performance to make sure the company can sustain itself down the road.Use Amgen to protect against small markets fluctuations. The stock experiences normal downward trend and little activity. Check odds of Amgen to be traded at $184.25 in 30 days

Amgen Inc Valuation Over Time

Enterprise Value

Amgen Company Summary

Amgen competes with Quintiles IMS, Vertex Pharmaceuticals, Endo International, Abbott Laboratories, and ALLERGAN INC. It offers solutions for the treatment of illness in the areas of oncologyhematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. Amgen Incs solutions include Neulasta, a pegylated protein for the treatment of cancer patients NEUPOGEN, a recombinantmethionyl human granulocyte colonystimulating factor for reducing the incidence of infection for patients with nonmyeloid malignancies and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its solutions also comprise EPOGEN to treat a lowerthannormal number of red blood cells caused by chronic kidney disease in patients on dialysis Aranesp for treating anemia XGEVA for the prevention of skeletalrelated events Prolia to treat postmenopausal women with osteoporosis Repatha for the treatment of cholesterol and SensiparMimpara solutions for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Amgen Incs other marketed solutions include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and smallcell lung cancer Nplate, a thrombopoietic compound Vectibix, a human monoclonal antibody and BLINCYTO for the treatment of patients with Philadelphia chromosomenegative relapsed or refractory Bcell precursor acute lymphoblastic leukemia. It also develops various solutions that are in various clinical trials. Amgen Inc serves pharmaceutical wholesale distributors and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc UCB Novartis AG Bayer HealthCare Pharmaceuticals Inc Advaxis, Inc. Dr. Reddys Laboratories Ltd. Biocartis Group NV and Nuevolution AB. Amgen Inc also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Amgen Number of Shares Shorted vs Current Asset

Amgen Inc is rated second in number of shares shorted category among related companies. It is number one stock in current asset category among related companies fabricating about  4,932  of Current Asset per Number of Shares Shorted.

Amgen Fundamentals

 Better Than Average     
 Worse Than Average Compare Amgen to competition
FundamentalsAmgenPeer Average
Return On Equity26.43 % (15.17) %
Return On Asset8.27 % (15.64) %
Profit Margin35.46 % (5.50) %
Operating Margin44.49 % (10.91) %
Current Valuation132.63 B152.14 B
Shares Outstanding729.68 M1.43 B
Shares Owned by Insiders0.14 % 6.91 %
Shares Owned by Institutions80.47 % 18.37 %
Number of Shares Shorted7.81 M3.24 M
Price to Earning16.97 times40.69 times
Price to Book4.29 times14.44 times
Price to Sales5.90 times17.81 times
Revenue23.05 B9.85 B
Gross Profit18.83 B21.75 B
EBITDA12.36 B1.41 B
Net Income8.17 B517.71 M
Cash and Equivalents39.23 B3.89 B
Cash per Share53.76 times5.17 times
Total Debt35.06 B7.36 B
Debt to Equity110.50 times0.72 times
Current Ratio6.20 times3.30 times
Book Value Per Share43.41 times13.64 times
Cash Flow from Operations10.47 B1.25 B
Short Ratio2.81 times2.09 times
Earnings Per Share10.98 times2.30 times
Price to Earnings To Growth3.63 times1.22 times
Number of Employees17.9 K10.67 K
Market Capitalization135.93 B29.78 B
Total Asset71.58 B126.86 B
Retained Earnings(438 M)38.24 B
Working Capital29.85 B3.58 B
Current Asset38.52 B36.8 B
Current Liabilities8.67 B33.34 B
Z Score1.8708.73
Five Year Return1.93 %
Last Dividend Paid4.6
< 25% 

Chance of Financial Distress

Amgen Inc has less than 25 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info


Amgen Growth Changes

EPS Diluted Growth

EPS Growth

NCFO Growth


Compare Amgen To Peers
Robert Bradway Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee
Brian McNamee Executive Vice President - Full Potential Initiatives
More Executives

Opportunity Range

September 26, 2017 Opportunity Range